Science news

<<  return

 

Shortening Dual Antiplatelet Therapy Ups MI Risk in ACS

Reducing dual antiplatelet therapy (DAPT) to 6 months in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stent placement was associated with an increased risk for myocardial infarction, in the SMART-DATE trial.

Gwon presented the SMART-DATE trial at the American College of Cardiology (ACC) 2018 Annual Scientific Session. The study was also simultaneously published online in The Lancet.

  1. Lancet. Published online March 12, 2018.  AbstractComment
  2. www.medscape.com